Special Issue

Noncoding RNAs (ncRNAs): The Role in Gene Regulation and Human Diseases

Message from the Guest Editors

Our Special Issue “Noncoding RNAs (ncRNAs): The Role in Gene Regulation and Human Diseases” mainly focus on the following researches: 1. Noncoding RNAs in genomic editing
By leveraging ncRNAs, researchers can develop targeted therapies for genetic disorders, improve the accuracy of gene editing, and reduce off-target effects. This precision is crucial for therapeutic applications, including cancer treatment, genetic disease correction, and regenerative medicine. 2. Noncoding RNA and epigenetics
Understanding the interplay between ncRNAs and epigenetic regulation is essential for unraveling complex biological processes and has significant implications for developing novel therapeutic strategies for various diseases. 3. ncRNAs in Stem Cell Biology and Regenerative Medicine
Noncoding RNAs (ncRNAs) are increasingly recognized as critical regulators in stem cell biology and regenerative medicine.

Guest Editors

Dr. Liming Chen
Weill Cornell Medicine, Cornell University, New York, NY, USA

Dr. Yuanshan Zhu
Department of Medicine and Clinical and Translational Science Center, Weill Cornell Medicine, Cornell University, New York, NY, USA

Deadline for manuscript submissions

closed (31 July 2025)

Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed

mdpi.com/si/208431

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines

Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed

mdpi.com/journal/biomedicines

MDPI

About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni
1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).